Clinical trials: Anti-Retroviral Agents
HIV Infections
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
The purpose of this study is to see if the addition of capravirine to VIRACEPT (nelfinavir mesylate) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is an effective combination drug therapy for HIV patients who have…
- Trial name
- NCT00006211
- Testing
- Capravirine, Nelfinavir mesylate
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Agouron Pharmaceuticals
Medication Adherence, HIV Drug Resistance
Sustainable Adherence and Prevention of HIV Drug Resistance in Adolescents
The overall goal of this study is to determine if implementation of a package of interventions that includes DBS-based VL monitoring, coupled with an evidence-based intervention to improve ART adherence using cognitive-behavioral…
- Trial name
- SAPHRA (NCT03928834)
- Testing
- Adapted Nzira Itsva
- Where
- Zimbabwe
- Sponsor
- University of Zimbabwe
Intravenous Drug Abuse
Pre-exposure Prophylaxis (PrEP) for People Who Inject Drugs (PWID)
People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID…
- Trial name
- NCT03869671
- Testing
- PrEP uptake/adherence intervention, Harm reduction standard of care
- Sponsor
- Boston University
HIV-1
Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1
The presence of a pool of cells latently infected by HIV-1 in patients taking HAART and with a viral load below 50 copies/mL is the main limitation to eradication of the virus from the body.
- Trial name
- NCT00795444
- Testing
- maraviroc
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections, Tuberculosis
Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
Successful therapy of both tuberculosis and HIV disease share similar problems: pill burden, drug interaction, adherence challenge and toxicity.
- Trial name
- NCT00115609
- Testing
- efavirenz, tenofovir DF, emtricitabine
- Where
- France
- Volunteers
- 70 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in South Africa.
- Trial name
- ENABLE 1 (NCT07655128)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl)
- Volunteers
- 87 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections
Viracept Expanded Access Program
To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who…
- Trial name
- NCT00002165
- Testing
- Nelfinavir mesylate
- Where
- United States
- Sponsor
- Agouron Pharmaceuticals
HIV
Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects
The purpose of this research study is to find out how the drugs Truvada® (tenofovir/emtricitabine), Isentress® (raltegravir), Reyataz® (atazanavir), Sustiva® (efavirenz), and Selzentry® (maraviroc) get into the intestines and the…
- Trial name
- NCT02641444
- Testing
- Blood plasma collection, Cervical and Vaginal Biopsy, Colonoscopy with Ileal and Rectal Biopsy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Pediatric Expanded Access Program-Oral Solution (0831-908)
Monitor the safety and tolerability of efavirenz oral solution in combination with Antiretroviral Therapy for the treatment of patients age 3 to 16 years who have failed therapy or who are intolerant to their current therapy.
- Trial name
- NCT00543530
- Testing
- MK0831
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections, HIV Infections
A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients
To define relationships between 1) HIV load and risk of CMV disease, 2) CMV load and the risk of developing CMV disease, and 3) CMV load and HIV load.
- Trial name
- NCT00001089
- Where
- 36 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only
The purpose of this study is to evaluate the proportion of patients with viral load of HIV-1 < 50 copies after 48 weeks of follow-up after randomization to change or not to nevirapine.
- Trial name
- NCT00415090
- Testing
- Nevirapine
- Where
- 17 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Hospital de Calella
Human Immunodeficiency Viruses
Implementing Long-Acting Novel Antiretrovirals
This is a 12-month, dual arm, phase 4, open-label, multi-centre study examining the implementation of LA intra-muscular (IM) drugs in clinics and decentralised community-based settings in the UK.
- Trial name
- ILANA (NCT05294159)
- Testing
- The Feasibility of Intervention Measure (FIM) and Acceptability of Intervention Measure (AIM)
- Where
- 6 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- Queen Mary University of London
HIV Infections, Pregnancy
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth.
- Trial name
- NCT00000888
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety Study of Once a Day ART and Opiate Substitute.
This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.
- Trial name
- 3OD (NCT00324688)
- Testing
- Viread
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Women's Health, HIV Infection
Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
Increases in cluster of differentiation 4 (CD4)+ T cells in the blood is well documented in human immunodeficiency virus (HIV)-infected individuals after starting antiretroviral therapy (ART), but increases CD4+ T cells in the…
- Conditions
- Women's Health, HIV Infection, Genital Diseases, Female
- Trial name
- NCT01456962
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
HIV Infections
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human…
- Trial name
- NCT00352053
- Testing
- Tenofovir DF
- Where
- 18 sites in Brazil, Panama
- Volunteers
- 87 people
- Sponsor
- Gilead Sciences
HIV-1-infection
Euphorbia Kansui and HIV/AIDS Functional Cure
The purpose of this study is to determine the safety and bioactivity of Euphorbia kansui, which has been used in traditional Chinese medicine for the treatment of edema, ascites, and asthma.
- Trial name
- NCT04503928
- Testing
- Euphorbia kansui Pill
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV-1 Infected Adults With Chronic HIV-1 Infection
Enhancement by Poly-ICLC During HIV-1 Infection
This study involves researching new approaches to treating HIV infection. Currently, HIV infection is treated with combinations of drugs called antiretrovirals.
- Trial name
- Poly-ICLC (NCT02071095)
- Testing
- Arm A: Poly-ICLC, Arm B: Normal Saline
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nina Bhardwaj
HIV Infections, Emphysema
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Despite the availability of highly active antiretroviral therapy (HAART), lung diseases remain a leading cause of morbidity and mortality in those with HIV infection.
- Conditions
- HIV Infections, Emphysema, Chronic Obstructive Pulmonary Disease, Pneumocystis
- Trial name
- MACS (NCT00870857)
- Where
- 2 sites in United States
- Volunteers
- 407 people
- Sponsor
- University of Pittsburgh
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART).
- Conditions
- Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
- Trial name
- NCT05261191
- Testing
- MGD020, MGD014
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- MacroGenics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.